SCHEMBL4528455

SCHEMBL4528455

NNC(CCC(=O)O)C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 6/20 0.61
NAALAD2 Q9Y3Q0 3/20 0.61
RIMKLA Q8IXN7 1/20 0.61
GNPAT O15228 2/20 0.61
GGH Q92820 1/20 0.52
GRM8 O00222 1/20 0.50
GRM6 O15303 1/20 0.50
GRIN2D O15399 1/20 0.50
GRIN3B O60391 1/20 0.50
GSR P00390 1/20 0.50
CYP1A2 P05177 1/20 0.50
GRIK1 P39086 1/20 0.50
GRM5 P41594 1/20 0.50
GRIA1 P42261 1/20 0.50
GRIA2 P42262 1/20 0.50
GRIA3 P42263 1/20 0.50
SLC1A3 P43003 1/20 0.50
SLC1A2 P43004 1/20 0.50
SLC1A1 P43005 1/20 0.50
GRIA4 P48058 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL538658 1.00 FOLH1 (0.61) FOLH1NAALAD2RIMKLAGNPATGGH
SCHEMBL14625016 1.00 FOLH1 (0.61) FOLH1NAALAD2RIMKLAGNPATGGH
SCHEMBL27608194 0.98 GNPAT (0.59) FOLH1NAALAD2RIMKLAGNPATGGH
Formic Acid SCHEMBL30874324 0.92 GNPAT (0.54) FOLH1NAALAD2RIMKLAGNPATGGH
SCHEMBL13465054 0.84 FOLH1 (0.48) FOLH1NAALAD2RIMKLAGNPATGGH
SCHEMBL4760379 0.84 KMT2A (0.52) FOLH1NAALAD2RIMKLAGNPATGGH
SCHEMBL18467856 0.84 FOLH1 (0.48) FOLH1NAALAD2RIMKLAGNPATGGH
SCHEMBL1332365 0.84 KMT2A (0.52) FOLH1NAALAD2RIMKLAGNPATGGH
SCHEMBL1332255 0.84 KMT2A (0.52) FOLH1NAALAD2RIMKLAGNPATGGH
SCHEMBL4760380 0.84 KMT2A (0.52) FOLH1NAALAD2RIMKLAGNPATGGH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104090095-A Molecular conjugate VENTANA MED SYST INC 2014-10-08 CN claimed
CN-101029131-A Branching poly-ethylene and its production NAT DEFENCE SCIENCE & TECHNOLO (CN) 2007-09-05 CN claimed
CN-117510828-A Tri-arm polyethylene glycol derivative containing amino acid residue 厦门赛诺邦格生物科技股份有限公司 2024-02-06 CN disclosed
CN-116332831-A Purification method of 3-amino-5-methylpiperidine with amino protected by Boc 浙江医药股份有限公司新昌制药厂 2023-06-27 CN disclosed
EP-3720472-A1 INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN HAVING A PI OF BETWEEN 5.8 AND 8.5 AND A COPOLYAMINO ACID CARRYING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS Adocia (FR) 2020-10-14 EP disclosed
CN-110462038-A Anti- GPRC5D antibody and the molecule comprising the antibody DAIICHI SANKYO CO LTD 2019-11-15 CN disclosed
EP-3087392-B1 MENTAL ILLNESS MODEL AND MENTAL ILLNESS RISK ASSESSMENT TEST FOR SCHIZOPHRENIC PSYCHOSIS WILLIAMS STEPHANIE SUE (AU) 2018-10-31 EP disclosed
CN-108135908-A For the combination treatment for the treatment of cancer EPIZYME股份有限公司 2018-06-08 CN disclosed
CN-104220210-B Flux for soldering and solder composition 富士电机株式会社 2017-12-01 CN disclosed
EP-2875035-A1 METHOD FOR THE SYNTHESIS OF ALPHA-AMINOALKYLENEPHOSPHONIC ACID Straitmark Holding AG (CH) 2015-05-27 EP disclosed
CN-104126012-A Bioconversion process for producing nylon-7, nylon-7,7 and polyesters INVISTA TECH SARL 2014-10-29 CN disclosed
US-20070032417-A1 Peptides and therapeutic uses thereof WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) 2007-02-08 US disclosed
WO-2006000034-A1 CONJUGATES AND THERAPEUTIC USES THEREOF THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) 2006-01-05 WO disclosed
CN-1611524-A Polyethylene glycol amino acid N-internal ring carbonyl anhydride active derivatives, and medicinal bonding compound and gel thereof JIANKAI SCI & TECH CO LTD BEIJ (CN) 2005-05-04 CN disclosed
WO-2004058804-A1 PEPTIDES AND THERAPEUTIC USES THEREOF WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) 2004-07-15 WO disclosed
CN-1476325-A Delivery system for active substances and method for protecting and administering active substances 新河药品股份有限公司 2004-02-18 CN disclosed
WO-1997015676-A2 CANDIDA TOPOISOMERASEIGENE ABBOTT LABORATORIES (US) 1997-05-01 WO disclosed
CN-1030353-C Nonlinear optical materials DU PONT (US) 1995-11-22 CN disclosed
CN-1059344-A Nonlinear optical material DU PONT (US) 1992-03-11 CN disclosed
US-4515891-A ENZYMATIC HYDROLYSIS OF CELL WALLS OF LACTOBACILLUS OR CORYNEBACTERIUM DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 1985-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032417-A1 Peptides and therapeutic uses thereof BCL2, BAX, BCL2L13 FOLH1 1648/4885NAALAD2 2552/4885RIMKLA 3592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.